RecruitingNCT06696417
Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
Studying Hinman syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- First Hospital of China Medical University
- Intervention
- Drug group：vunakizumab (IL-17A inhibitor)(drug)
- Enrollment
- 1516 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (1)
- The First Hospital of China Medical University, Shenyang, Liaoning, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06696417 on ClinicalTrials.govOther trials for Hinman syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07307274A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight AdultsSyntis Bio
- ACTIVE NOT RECRUITINGPHASE2NCT07281937A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesVerdiva Bio Dev Limited
- ENROLLING BY INVITATIONNANCT07283107Trial to Evaluate the Impact of Various Behavioural Interventions to Increase Mammography Uptake Among Singaporean WomenNational University Hospital, Singapore
- RECRUITINGNANCT07268508Impact of a Pro-diversity Gut Microbiota Diet After a Bariatric Surgery on Gut Microbiota, Eating Behaviour and Sensory FunctionHospices Civils de Lyon
- RECRUITINGPHASE2NCT06927739Focused Orticumab Research for Treating Inflammation in Coronary ArteriesAbcentra
- RECRUITINGNANCT07054333Objective Measurement of Pain Regulation in Individuals Who Have Received Internet-delivered Exposure-based Cognitive Behavior TherapyKarolinska Institutet
- RECRUITINGPHASE4NCT07030517A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple MyelomaJohnson & Johnson Private Limited
- RECRUITINGPHASE2NCT06846320Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety DisorderAbbVie